Search research articles
Contact Us
Filters
Showing results (231-240 of 256) with videos related to
Page
of 26
Sort By:
Annals of Surgical Oncology
|
November 30, 2024
Prehabilitation Outcomes in Surgical Oncology Patients Undergoing Major Abdominal Surgery: A Meta-analysis of Randomized Control Trials
Natalie Hann Soh, Charles Rong Zhang Yau, Xi Zhi Low, et al.
Annals of Surgical Oncology
|
February 24, 2025
ASO Visual Abstract: Prehabilitation Outcomes in Surgical Oncology Patients Undergoing Major Abdominal Surgery-A Meta-Analysis of Randomized Control Trials
Natalie Hann Soh, Charles Rong Zhang Yau, Xi Zhi Low, et al.
Journal of Surgical Education
|
September 19, 2025
Palliative Care Education Programs for Surgeons: A Review of Current Curriculum and Education Outcomes
Sabrina Hui Xian Cheok, Benjamin Paik, Hann Natalie Soh, et al.
British Journal of Cancer
|
April 1, 2010
Risks of second primary cancer among patients with major histological types of lung cancers in both men and women
S-C Chuang, G Scélo, Y-C A Lee, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 11, 2008
Risk of second malignant neoplasms after childhood central nervous system malignant tumours: an international study
M Maule, G Scélo, G Pastore, et al.
Breast Cancer Research : BCR
|
August 31, 2023
Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrant
P Neven, P A Fasching, S Chia, et al.
Diabetologia
|
May 6, 2009
Microarray analysis of multiple candidate genes and associated plasma proteins for nephropathy secondary to type 2 diabetes among Chinese individuals
S C Lim, J J Liu, H Q Low, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 8, 2021
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival
D J Slamon, P Neven, S Chia, et al.
Journal of the Economics of Ageing
|
December 21, 2019
The Long-Term Impact of Functional Disability on Hospitalization Spending in Singapore
C Chen, J T Lim, N C Chia, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 20, 2021
Corrigendum to 'Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival': [Annals of Oncology Volume 32, Issue 8, August 2021, Pages 1015-1024]
D J Slamon, P Neven, S Chia, et al.
Page
of 26
Search research articles
Search
Showing results (231-240 of 256) with videos related to
Sort By:
Page
of 26
Annals of Surgical Oncology
|
November 30, 2024
Prehabilitation Outcomes in Surgical Oncology Patients Undergoing Major Abdominal Surgery: A Meta-analysis of Randomized Control Trials
Natalie Hann Soh, Charles Rong Zhang Yau, Xi Zhi Low, et al.
Annals of Surgical Oncology
|
February 24, 2025
ASO Visual Abstract: Prehabilitation Outcomes in Surgical Oncology Patients Undergoing Major Abdominal Surgery-A Meta-Analysis of Randomized Control Trials
Natalie Hann Soh, Charles Rong Zhang Yau, Xi Zhi Low, et al.
Journal of Surgical Education
|
September 19, 2025
Palliative Care Education Programs for Surgeons: A Review of Current Curriculum and Education Outcomes
Sabrina Hui Xian Cheok, Benjamin Paik, Hann Natalie Soh, et al.
British Journal of Cancer
|
April 1, 2010
Risks of second primary cancer among patients with major histological types of lung cancers in both men and women
S-C Chuang, G Scélo, Y-C A Lee, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 11, 2008
Risk of second malignant neoplasms after childhood central nervous system malignant tumours: an international study
M Maule, G Scélo, G Pastore, et al.
Breast Cancer Research : BCR
|
August 31, 2023
Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrant
P Neven, P A Fasching, S Chia, et al.
Diabetologia
|
May 6, 2009
Microarray analysis of multiple candidate genes and associated plasma proteins for nephropathy secondary to type 2 diabetes among Chinese individuals
S C Lim, J J Liu, H Q Low, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 8, 2021
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival
D J Slamon, P Neven, S Chia, et al.
Journal of the Economics of Ageing
|
December 21, 2019
The Long-Term Impact of Functional Disability on Hospitalization Spending in Singapore
C Chen, J T Lim, N C Chia, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 20, 2021
Corrigendum to 'Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival': [Annals of Oncology Volume 32, Issue 8, August 2021, Pages 1015-1024]
D J Slamon, P Neven, S Chia, et al.
Page
of 26